RGN-259 ophthalmic solution

RGN-259 · ReGenTree, LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for RGN-259 ophthalmic solution, covering 2022-01-05 to 2026-08-28. Get the full timeline:

Most recent: Clinical Trial Results: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 [Phase 3]